Results 11 to 20 of about 11,837 (160)

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

Infectious Diseases and Therapy, 2023
Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Alex Soriano, Philippe Montravers, Matteo Bassetti, Galina Klyasova, George Daikos, Paurus Irani, Gregory Stone, Richard Chambers, Pascale Peeters, Mitesh Shah, Claire Hulin, Natalia Albuquerque, Efim Basin, Benjamin Gaborit, Irene Kourbeti, Francesco Menichetti, María Teresa Perez-Rodriguez, Mathias W. Pletz, Marisa Sanchez, Ivan Trompa, Anita Verma, Maria Lavinea N. de Figueiredo, Claudie Charbonneau   +22 more
doaj   +2 more sources

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +2 more sources

Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.

PLoS ONE
NDM-producing carbapenem-resistant bacterial infections became a challenge for clinicians. Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections.
Salman Khan, Arghya Das, Deepali Vashisth, Anwita Mishra, Ashima Jain Vidyarthi, Raghav Gupta, Nazneen Nahar Begam, Babita Kataria, Sushma Bhatnagar   +8 more
doaj   +2 more sources

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi   +10 more
doaj   +2 more sources

Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview

Antimicrobial Agents and Chemotherapy, 2022
First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have encountered a worldwide success, particularly in K. pneumoniae isolates.
C. Hobson, G. Pierrat, O. Tenaillon, S. Bonacorsi, Béatrice Berçot, Ella Jaouen, H. Jacquier, A. Birgy   +7 more
semanticscholar   +1 more source

Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria

Антибиотики и Химиотерапия, 2021
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj   +1 more source

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing

Antibiotics, 2022
Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained by MDR pathogens.
P. Gaibani, Tommaso Giani, Federica Bovo, D. Lombardo, Stefano Amadesi, T. Lazzarotto, M. Coppi, G. Rossolini, S. Ambretti   +8 more
semanticscholar   +1 more source

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae

Emerging Infectious Diseases, 2023
We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui, Chen Wang, Qichen Wang, Juanxiu Qin, Min Li, Baixing Ding, Zhen Shen   +6 more
doaj   +1 more source

Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Antimicrobial Resistance and Infection Control, 2020
Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang, Yingchun Xu, Peiyao Jia, Ying Zhu, Ge Zhang, Jingjia Zhang, Simeng Duan, Wei Kang, Tong Wang, Ran Jing, Jingwei Cheng, Yali Liu, Qiwen Yang   +12 more
doaj   +1 more source

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

Antibiotics, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos, Clóvis Arns da Cunha, Gian Maria Rossolini, Gregory G. Stone, Nathalie Baillon-Plot, Margaret Tawadrous, Paurus Irani   +6 more
doaj   +1 more source